(Circulation. 2001;103:2236.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina
From the Department of Cardiology, Catholic University, Rome, Italy
Correspondence to Giovanna Liuzzo, MD, PhD, Cardiology, Catholic University, Largo A. Gemelli, 8-00168 Rome, Italy. E-mail gliuzzo{at}hotmail.com
Background—C-reactive protein (CRP) plasma levels have been associated with short- and long-term occurrence of coronary events. We investigated whether circulating inflammatory cell responsiveness to low-grade stimuli could contribute to the reported association between CRP and coronary events.
Methods and Results—We studied 32 patients with unstable angina who were followed for 24 months and were free of symptoms for 6 months (group 1): 19 patients had persistently high CRP levels (>0.3 mg/dL) (group 1A); 13 patients had normal CRP levels (group 1B). During the follow-up, 12 (63%) group 1A but no group 1B patients developed an infarction or recurrence of unstable angina (P<0.001). Eighteen patients with chronic stable angina (group 2) and 18 healthy subjects (group 3) were studied as controls. Interleukin (IL)-6 production (median, range) by peripheral blood mononuclear cells after 4 hours of in vitro stimulation with 1 ng/mL lipopolysaccharide (LPS) was significantly higher in group 1A (4526 pg/mL, 3042 to 10 583 pg/mL) than in group 1B (1752 pg/mL, 75 to 3981 pg/mL), group 2 (707 pg/mL, 41 to 3275 pg/mL), and group 3 (488 pg/mL, 92 to 3503 pg/mL) (all P<0.001). No significant differences were observed among the other groups. IL-6 production after LPS-challenge was correlated with baseline CRP levels (r=0.42, P=0.005).
Conclusions—Mononuclear cells of patients with recurrent phases of instability exhibit an enhanced production of IL-6 in response to low-dose of LPS, correlated with baseline CRP levels, 6 months after the last acute event. This persisting enhanced acute-phase responsiveness may help explain the association between CRP and acute coronary events.
Key Words: angina • inflammation • interleukins • leukocytes • prognosis
This article has been cited by other articles:
 |
|
 |
|
  E. A. Nicu, M. L. Laine, S. A. Morre, U. Van der Velden, and B. G. Loos Soluble CD14 in periodontitis Innate Immunity, April 1, 2009; 15(2): 121 - 128. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Pasterkamp and M. Daemen Circulating cells: the biofactory for markers of atherosclerotic disease Eur. Heart J., November 2, 2008; 29(22): 2701 - 2702. [Full Text] [PDF]
|
|
|
|
 |
|
 D Versteeg, I E Hoefer, A H Schoneveld, D P V de Kleijn, E Busser, C Strijder, M Emons, P R Stella, P A Doevendans, and G Pasterkamp Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve Heart, June 1, 2008; 94(6): 770 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liuzzo, L. M. Biasucci, G. Trotta, S. Brugaletta, M. Pinnelli, G. Digianuario, V. Rizzello, A. G. Rebuzzi, C. Rumi, A. Maseri, et al. Unusual CD4+CD28null T Lymphocytes and Recurrence of Acute Coronary Events J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1450 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ray, D. A. Morrow, M. S. Sabatine, A. Shui, N. Rifai, C. P. Cannon, and E. Braunwald Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome Circulation, June 19, 2007; 115(24): 3071 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Liuzzo, G Giubilato, and M Pinnelli T cells and cytokines in atherogenesis Lupus, September 1, 2005; 14(9): 732 - 735. [Abstract] [PDF]
|
|
|
|
|
|
H. Methe, S. Brunner, D. Wiegand, M. Nabauer, J. Koglin, and E. R. Edelman Enhanced T-Helper-1 Lymphocyte Activation Patterns in Acute Coronary Syndromes J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1939 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Methe, J.-O. Kim, S. Kofler, M. Weis, M. Nabauer, and J. Koglin Expansion of Circulating Toll-Like Receptor 4-Positive Monocytes in Patients With Acute Coronary Syndrome Circulation, May 24, 2005; 111(20): 2654 - 2661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L M Biasucci, M Lombardi, M Piro, G Di Giannuario, G Liuzzo, and F Crea Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina Heart, May 1, 2005; 91(5): 670 - 671. [Full Text] [PDF]
|
|
|
|
|
|
M. Valgimigli, C. Ceconi, P. Malagutti, E. Merli, O. Soukhomovskaia, G. Francolini, G. Cicchitelli, A. Olivares, G. Parrinello, G. Percoco, et al. Tumor Necrosis Factor-{alpha} Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction: The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study Circulation, February 22, 2005; 111(7): 863 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Arroyo-Espliguero, P Avanzas, S Jeffery, and J C Kaski CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart, September 1, 2004; 90(9): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Monakier, M. Mates, M. W. Klutstein, J. A. Balkin, B. Rudensky, D. Meerkin, and D. Tzivoni Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes Chest, May 1, 2004; 125(5): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, M. M. Hoffmann, W. Marz, M. Frohlich, A. Hoffmeister, H. Brenner, and D. Rothenbacher CD14 C(-260)->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 34 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Halushka and P. V. Halushka Why Are Some Individuals Resistant to the Cardioprotective Effects of Aspirin?: Could It Be Thromboxane A2? Circulation, April 9, 2002; 105(14): 1620 - 1622. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ray, A. M. Lincoff, E. J. Topol, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, and M. T. Nakada Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization * Response Circulation, March 26, 2002; 105 (12): e74 - e74. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maseri and D. Cianflone Inflammation in acute coronary syndromes Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B8 - B13. [Abstract] [PDF]
|
|